All of us are entitled to a change of heart. But when you're one of the world's most famous activist investors and the change involves a decent-sized stake in a drug maker (Allergan) that just 5 months ago was mixed up with a target of your serious criticism (that would be the ill-fated Pfizer/Allergan deal), people are sure to take notice – NYTimes and WSJ and Bloomberg